Skip to main content

Table 4 Univariate analysis of factors associated with LTFU among HIV-infected adults on antiretroviral therapy

From: Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya

 Univariable Results (n = 23890)
6 months12 months24 months36 months
OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
Gender
 Male1.25 (1.15–1.37)< 0.0011.18 (1.09–1.27)< 0.0011.13 (1.06–1.21)< 0.0011.12 (1.06–1.19)< 0.001
 FemaleRef Ref Ref Ref 
Age groups
 20–351.18 (1.08–1.29)< 0.0011.31 (1.21–1.41)< 0.0011.42 (1.33–1.51)< 0.0011.43 (1.34–1.51)< 0.001
 36–50Ref Ref Ref Ref 
 51+1.00 (0.86–1.16)0.9670.97 (0.85–1.10)0.6070.95 (0.85–1.07)0.4190.97 (0.87–1.08)0.555
Marital Status
 Single1.38 (1.22–1.55)< 0.0011.34 (1.21–1.48)< 0.0011.27 (1.16–1.39)< 0.0011.34 (1.24–1.45)< 0.001
 Divorced1.44 (1.29–1.62)< 0.0011.41 (1.28–1.56)< 0.0011.4 (1.28–1.52)< 0.0011.33 (1.23–1.44)< 0.001
 MarriedRef Ref Ref Ref 
 Widowed0.99 (0.85–1.14)0.8330.94 (0.83–1.06)0.2800.94 (0.85–1.04)0.2430.94 (0.85–1.04)0.214
BMI
 < 18.51.65 (1.41–1.94)< 0.0011.48 (1.31–1.67)< 0.0011.33 (1.20–1.47)< 0.0011.23 (1.13–1.34)< 0.001
 18.5–24.9Ref Ref Ref Ref 
 25–29.90.54 (0.41–0.72< 0.0010.58 (0.46–0.73)< 0.0010.63 (0.53–0.76)< 0.0010.66 (0.58–0.76)< 0.001
 30+0.49 (0.36–0.66)< 0.0010.50 (0.41–0.69)< 0.0010.61 (0.51–0.73)< 0.0010.67 (0.57–0.8)< 0.001
CD4
 0–2501.70 (1.47–1.96)< 0.0011.6 (1.42–1.80)< 0.0011.34 (1.22–1.47)< 0.0011.30 (1.20–1.41)< 0.001
 251–500Ref Ref Ref Ref 
 Above 5001.91 (1.09–3.32)0.0231.55 (0.94–2.55)0.0861.70 (1.13–2.56)0.0111.53 (1.05–2.25)0.028
Regimen Started
 D4T-basedRef Ref Ref Ref 
 ABC-based2.09 (1.62–2.68)< 0.0012.17 (1.74–2.73)< 0.0012.15 (1.74–2.66)< 0.0012.01 (1.63–2.48)< 0.001
 AZT-based0.66 (0.59–0.75)< 0.0010.69 (0.62–0.76)< 0.0010.73 (0.67–0.80)< 0.0010.81 (0.75–0.88)< 0.001
 TDF-based0.57 (0.51–0.64)< 0.0010.62 (0.56–0.68)< 0.0010.69 (0.64–0.75)< 0.0010.81 (0.75–0.87)< 0.001
Baseline WHO Stage
 Stage IRef Ref Ref Ref 
 Stage II1.16 (0.99–1.37)0.07071.19 (1.04–1.36)0.011.13 (1.01–1.26)0.0321.11 (1.02–1.22)0.0230
 Stage III1.76 (1.51–2.06)< 0.0011.63 (1.44–1.84)< 0.0011.46 (1.32–1.61)< 0.0011.38 (1.26–1.50)< 0.001
 Stage IV2.45 (1.98–3.04)< 0.0011.99 (1.66–2.39)< 0.0011.63 (1.40–1.91)< 0.0011.53 (1.31–1.78)< 0.001